At Mullan, we are committed to expanding access to safe and effective medications worldwide. With over 1,200 FDA-approved products, we are currently focused on serving the US market, but we plan to register them in more markets in the future as part of our ongoing mission to benefit patients across the globe. 

Mullan was founded in 2022 as a subsidiary of Pasaca Capital. As a Pasaca company, we are committed to serving the global community by creating value through our business. Pasaca’s expertise in distribution and operations, combined with a strong capital base and extensive global network, provide us with the resources we need to pursue our vision.